Brand: BioGaia

Osfortis 60 capsules

In Stock

Adding to cart… The item has been added

Product Description

BioGaia Osfortis - Probiotic capsules with vitamin D

BioGaia Osfortis is a probiotic dietary supplement containing the patented lactic acid bacterium Lactobacillus reuteri Osfortis (Lactobacillus reuteri ATCC PTA 6475) and vitamin D3. Vitamin D contributes to the maintenance of normal bones. Because L. reuteri Osfortis naturally colonizes humans it has a strong adaptation to persist and interact with humans. L. reuteri Osfortis has been tested in clinical trials and proven effective and safe.


Lactobacillus reuteri ATCC PTA 6475 (L. reuteri Osfortis) 10 billion CFU, Vitamin D (as cholecalciferol) 10 mg (400 IU), Maltodextrin, magnesium stearate, hydroxypropyl methylcellulose (capsule).

Serving Size

One capsule twice daily, with or without food. Use regularly for bone health. The recommended daily dose should not be exceeded.


  • Storage: Store in a dry place at room temperature (77°F) or below.
  • Keep out of reach of children.
  • Open container should be used within 60 days.
  • Close the cap tightly after each use to reduce moisture.

Osfortis Press Release

BioGaia (Stockholm, Sweden) has launched a new bone health product called BioGaia Osfortis in the U.S. market, distributed by Everidis Health Sciences (St. Louis, MO). The product is unique because it combines BioGaia’s proprietary Lactobacillus reuteri ATCC PTA 6475 strain with vitamin D. A randomized, placebo-controlled, double-blind study1 published last year found that supplementation with BioGaia’s probiotic strain for 12 months reduced the loss of volumetric bone mineral density by half in elderly women with low bone density, compared to placebo. This research validated results found in animal studies and justified further investigation of the probiotic strain in relation to bone health.

“Osteoporosis is a common, global disease. Consequently, a way of maintaining good bone health constitutes an important focus area for BioGaia. I am very happy that our partner Everidis is launching BioGaia Osfortis in the USA. It is an important market with great potential for this product. Step by step, more markets will launch BioGaia Osfortis,” said Isabelle Ducellier, CEO of BioGaia, in a press release.


1. Nilsson A.G. et al. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo?controlled, double?blind, clinical trial." Journal of Internal Medicine, vol. 284, no. 3 (2018): 307-317